Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Companies

Boehringer Looks To Revitalise Its Pipeline

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.

Sales & Earnings Companies

Bayer’s Nubeqa Study Success Will Broaden Its Prostate Cancer Reach

The Phase III study success is good news, but not the surprise upside that Bayer needs to lift investor sentiment.

Clinical Trials Cancer

Roche Could Have The Best Obesity Pill

That is, if very early data in a handful of patients are borne out in later, larger studies.

Companies Metabolic Disorders

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

Financing Cardiovascular

CordenPharma Will Scale Up To Address GLP-1 Shortage

The Swiss contractor said it will invest about $981m to increase manufacturing capacity for GLP-1 peptides in the US and EU, to fulfill API contracts worth more than $3bn.

Manufacturing Business Strategies

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

Revolution Medicine Gets Set For Phase III After Pancreatic Cancer Results

The company could be first to bring a multi-RAS inhibitor to market, and has NSCLC as well as pancreatic cancer in its sights.

Clinical Trials Commercial

Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class

The Switzerland-based company is ready to begin a Phase II study with a novel OGA inhibitor after raising $100m from a consortium of investors.

Commercial Companies

CNS Drugs Are Surprisingly Valuable

An analysis of the most valuable research-stage products pinpoints several neurological candidates – and a deeper dive into this segment shows more CNS therapies that look to be worth big money.

Clinical Trials Commercial

The Prospects For Earlier-Stage Antibody-Drug Conjugates

Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.

Clinical Trials Commercial

IPOs Collapse In The Second Quarter

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.

Financing Business Strategies

SciRhom Secures €63m Series A To Target Autoimmune Disease ‘Master Switch’

The Munich-based firm looks to pioneer the novel iRhom2 mechanism to dial down inflammation while maintaining immune homeostasis.

Commercial Financing

Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition

Chief scientific officer and president of Pfizer Research & Development Mikael Dolsten will depart the company after a successor is appointed, likely early next year.

Leadership Research & Development

Roche’s Susvimo Returns, But Destined To Be Vabysmo’s Support Act

The implantable eye treatment will be back on the market soon, but risk of eye infections and complications remain higher than with injectable treatments, meaning it will play second fiddle to Vabysmo.

Approvals Ophthalmic

Investors Hit The Alarm Bells As Indivior Issues Profit Warning

The UK group remains confident that the scale of the US opioid epidemic, driven by misuse of fentanyl, still represents a considerable opportunity but investors have reacted nervously to lower revenues coming from Sublocade.

Business Strategies Neurology
See All